Navigation Links
Sugar boosters could lead to cheap, effective treatments for chronic bacterial infections
Date:5/11/2011

(Boston) James Collins, a pioneering researcher in the new field of systems biology and a MacArthur Genius, says: "You know the old saying: 'a spoonful of sugar makes the medicine go down?' This is more like 'a spoonful of sugar makes the medicine work.'

Dr. Collins, a professor of Biomedical Engineering at Boston University who is also a Howard Hughes Medical Institute investigator and a core faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, is talking about his recent development of an effective, low-cost and surprising way to treat chronic bacterial infections, such as staph, strep, tuberculosis, and infections of the urinary tract.

He and his team of scientists discovered that a simple compound sugar dramatically boosts the effectiveness of first-line antibiotics. Their findings appear in the May 12 issue of Nature (online May 11th).

The Boston University researchers discovered that a simple compound sugar dramatically boosts the effectiveness of first-line antibiotics. Their findings appear in the May 12 issue of Nature.

Dr. Collins, 45, who is also a founder of the new field of synthetic biology, has a personal interest in this research. His 71 year old mother, Eileen Collins, was hospitalized several times in recent years with recurrent bouts of a serious staph infection. Doctors treated her with multiple intravenous antibiotics and still the infection could not be killed. It was his mother's suffering that added urgency to Dr. Collins' research. (While Mrs. Collins is not symptomatic at the moment, she is still on antibiotics).

In addition, his own undergraduate track career at the College of the Holy Cross years ago was cut short by a persistent staph infection. Despite repeated doses of erythromycin, the infection continued to sap his energy and he was unable to compete in his event the mile -- during his junior and senior years.

Chronic and recurrent infections are typically caused by bacterial 'persisters' a small subpopulation of bacteria that manage to survive an antibiotic onslaught by essentially shutting down and metabolically going into hibernation.

As a result, the patient initially appears to be fully recovered, but over the course of weeks or months, the persisters return to life, often stronger and more aggressive than ever before, and the patient relapses.

Bacterial persistence is a major obstacle in the successful treatment of infectious diseases. It can stretch illnesses out over months, cause infections to spread to kidneys and other organs, and send treatment costs soaring. Given its adverse clinical and public health impact, bacterial persistence has become a growing area of research.

Yet to date, no treatment directly targets bacterial persisters.

Unlike antibiotic-resistant bacteria, whose ability to withstand drug treatments is based on genetic mutations fostered by exposure to drug treatment, persisters are genetically identical to the other members of their bacterial community. What separates them from the pack is their ability to switch into power-save mode.

Dr. Collins' research team has now discovered an inexpensive and effective way to rouse these bacterial sleepers, using a simple weapon sugar to stimulate them into an active state in which they are just as vulnerable to antibiotics as the others in their community.

Dr. Collins' approach consists of adding sugar to the antibiotic. The sugar acts as a stimulant, essentially turning on normal bacterial responses, such as dying when confronted by a killer antibiotic.

Using this strategy on E. coli bacteria, a common cause of urinary tract infections, the team was able to eliminate 99.9 per cent of the persisters within just two hours - compared to no effect without sugar. The approach was similarly effective in killing Staphylococcus aureus bacteria, which cause sometimes deadly staph infections.

"Our goal was to improve the effectiveness of existing antibiotics, rather than invent new ones, which can be a long and costly process," says Collins' Boston University colleague, Kyle Allison, who was the first author on the study.

The findings have the potential to improve the lives of untold numbers of people who struggle with nagging infections, while also reducing healthcare costs substantially.

The most significant impact of this research could be on TB, a chronic bacterial infection that affects the lungs and causes more deaths than any other infections disease. The World Health Organization reports that approximately 4,700 people die from TB every day. An initial course of treatment typically takes five to nine months. Collins and Allison will next investigate whether sugar additives can improve the efficacy of TB drugs.


'/>"/>

Contact: Sara Rimer
srimer@bu.edu
917-602-5513
Boston University
Source:Eurekalert

Related biology technology :

1. Special sugar, nanoparticles combine to detect cholera toxin
2. Agrivida Announces Collaboration With Syngenta Ventures to Deliver Low-Cost Sugars for Cellulosic Biofuels and Biochemicals
3. Brazilian Sugarcane Industry Association Says Lame-Duck Congress Goes from Bad to Worse on Ethanol Policy
4. Researchers expand yeasts sugary diet to include plant fiber
5. Brazilian Sugarcane Industry Association Stresses Need for Brazils Government to Announce Ethanol Import Tariff Cut as Soon as Possible
6. EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline
7. Cautious Approach Needed Before Any Decision on EU Out-of-Quota Sugar Exports Is Taken
8. Ethanol Blend Reduction in Brazil Makes Sense Provided 90-Day Deadline is Respected, Says Brazilian Sugarcane Industry Association
9. Bunge Limited to Expand Sugar and Bioenergy Business in Brazil
10. Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane
11. Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):